E-QURE expects to initiate an FDA registration trial of its late-stage wound care device in Q3 2015 with top-line data due 4Q 2016; technology is first to mimic natural wound healing mechanisms at chronic wound sites; product economics not only extremely competitive, but also in line with existing U.S. reimbursement codes. Limited marketing underway in Europe under CE Mark--U.S. market launch anticipated for early 2017.